 The FDA has approved ChemoCentryx Incs NASDAQ: CCXI Tavneos avacopan as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis ANCA-associated vasculitis or ANCA vasculitis. Related: Adcomm Split On FDA Approval For ChemoCentryxs Vasculitis Candidate. 